Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
List view / Grid view
Structural Genomics Consortium (SGC)
Filter the results
27 January 2016 | By Victoria White
Myeloma UK and the SGC have entered into an open-access research partnership to discover drug targets for myeloma using structural biology and chemical proteomics...
In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...